» Articles » PMID: 34183713

MYD88, NFKB1, and IL6 Transcripts Overexpression Are Associated with Poor Outcomes and Short Survival in Neonatal Sepsis

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jun 29
PMID 34183713
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Toll-like receptor (TLR) family signature has been implicated in sepsis etiopathology. We aimed to evaluate the genetic profile of TLR pathway-related key genes; the myeloid differentiation protein 88 (MYD88), IL1 receptor-associated kinase 1 (IRAK1), the nuclear factor kappa-B1 (NFKB1), and interleukin 6 (IL6) in the blood of neonates with sepsis at the time of admission and post-treatment for the available paired-samples. This case-control study included 124 infants with sepsis admitted to the neonatal intensive care unit and 17 controls. The relative gene expressions were quantified by TaqMan Real-Time qPCR and correlated to the clinic-laboratory data. MYD88, NFKB1, and IL6 relative expressions were significantly higher in sepsis cases than controls. Higher levels of MYD88 and IL6 were found in male neonates and contributed to the sex-based separation of the cases by the principal component analysis. ROC analysis revealed MYD88 and NFKB1 transcripts to be good biomarkers for sepsis. Furthermore, patients with high circulatory MYD88 levels were associated with poor survival, as revealed by Kaplan-Meier curves analysis. MYD88, NFKB1, and IL6 transcripts showed association with different poor-outcome manifestations. Clustering analysis split the patient cohort into three distinct groups according to their transcriptomic signature and CRP levels. In conclusion, the study TLR pathway-related transcripts have a gender-specific signature, diagnostic, and prognostic clinical utility in neonatal sepsis.

Citing Articles

CRISPR: fundamental principles and implications for anaesthesia.

Perez A, Mavrothalassitis O, Chen J, Hellman J, Gropper M Br J Anaesth. 2025; 134(3):839-852.

PMID: 39855935 PMC: 11867086. DOI: 10.1016/j.bja.2024.11.040.


Pharmacological validation of a novel exopolysaccharide from sp. 139 to effectively inhibit cytokine storms.

Zhuang Z, Chen Y, Liu Z, Fu Y, Wang F, Bai L Heliyon. 2025; 10(14):e34392.

PMID: 39816356 PMC: 11734065. DOI: 10.1016/j.heliyon.2024.e34392.


CD5L as a promising biological therapeutic for treating sepsis.

Oliveira L, Silva M, Gomes A, Santos R, Cardoso M, Novoa A Nat Commun. 2024; 15(1):4119.

PMID: 38750020 PMC: 11096381. DOI: 10.1038/s41467-024-48360-8.


Genes regulating oxidative-inflammatory response in circulating monocytes and neutrophils in septic syndrome.

Elloumi N, Bahloul M, Benabdallah E, Kharrat S, Fakhfakh R, Bouchaala K Biol Futur. 2023; 74(1-2):199-207.

PMID: 37291472 DOI: 10.1007/s42977-023-00168-1.


Recent Advances on Small-Molecule Antagonists Targeting TLR7.

Zheng H, Wu P, Bonnet P Molecules. 2023; 28(2).

PMID: 36677692 PMC: 9865772. DOI: 10.3390/molecules28020634.


References
1.
Fry D . Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg. 2012; 78(1):1-8. View

2.
Bode C, Muenster S, Diedrich B, Jahnert S, Weisheit C, Steinhagen F . Linezolid, vancomycin and daptomycin modulate cytokine production, Toll-like receptors and phagocytosis in a human in vitro model of sepsis. J Antibiot (Tokyo). 2015; 68(8):485-90. PMC: 4579589. DOI: 10.1038/ja.2015.18. View

3.
Lai Y, Gallo R . Toll-like receptors in skin infections and inflammatory diseases. Infect Disord Drug Targets. 2008; 8(3):144-55. PMC: 2744356. DOI: 10.2174/1871526510808030144. View

4.
Naor R, Domankevich V, Shemer S, Sominsky L, Rosenne E, Levi B . Metastatic-promoting effects of LPS: sexual dimorphism and mediation by catecholamines and prostaglandins. Brain Behav Immun. 2008; 23(5):611-21. PMC: 2723727. DOI: 10.1016/j.bbi.2008.10.001. View

5.
Anwar M, Basith S, Choi S . Negative regulatory approaches to the attenuation of Toll-like receptor signaling. Exp Mol Med. 2013; 45:e11. PMC: 3584666. DOI: 10.1038/emm.2013.28. View